The market expects Boston Scientific (BSX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be ...

Boston Scientific Corporation (BSX) is scheduled to report third-quarter 2024 results on Oct. 23, before the opening bell.In the last reported quarter, the company’s earnings per share of 62 cents exceeded the Zacks Consensus Estimate by 6.9%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.18%, on average.Q3 EstimatesThe Zacks Consensus Estimate for third-quarter total revenues is pegged at $4.03 billion, suggestin ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 4.8% over the past month. The stock hit a new 52-week high of $87.79 in the previous session. Boston Scientific has gained 51.4% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the 14.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our e ...

Company Performance - Boston Scientific (BSX) closed at $86.20, down 0.58% from the previous trading session, underperforming the S&P 500 which lost 0.21% [1] - Over the past month, BSX shares gained 4.53%, outperforming the Medical sector's decline of 3.28% but lagging behind the S&P 500's increase of 5.94% [1] - The upcoming earnings report on October 23, 2024, is projected to show earnings of $0.58 per share, reflecting a year-over-year growth of 16%, with revenue expected to be $4.03 billion, indicating a 14.36% increase [1] Earnings Estimates - The full-year Zacks Consensus Estimates for BSX are earnings of $2.40 per share and revenue of $16.26 billion, representing year-over-year changes of +17.07% and +14.22%, respectively [2] - Recent changes to analyst estimates suggest a favorable outlook on the company's business health and profitability [2] Valuation Metrics - Boston Scientific has a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate increasing by 0.07% in the past month [3] - The company has a Forward P/E ratio of 36.12, which is a premium compared to the industry's average Forward P/E of 24.88 [3] - BSX's PEG ratio stands at 2.87, compared to the Medical - Products industry's average PEG ratio of 1.92 [3] Industry Overview - The Medical - Products industry is part of the Medical sector and holds a Zacks Industry Rank of 69, placing it in the top 28% of over 250 industries [4] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

After a commendable run in the first nine months of 2024, the S&P 500 is poised to gain in the year’s final three months. The S&P 500 has risen 20.8% in the first three quarters of the year, and historically whenever the broader index has gained over 20%, it has, on average, risen 2.1% in the fourth quarter, per Dow Jones Market Data.In the October-December quarter, the S&P 500’s median return was as high as 4.1%, and the index gained more than 77% of the time, added Dow Jones Market Data.The Federal Reserv ...

Company Performance - Boston Scientific (BSX) closed at $84.49, with a +0.42% change from the previous day's closing price, outperforming the S&P 500 which gained 0.01% [1] - Over the last month, Boston Scientific's shares increased by 3.7%, while the Medical sector experienced a loss of 3.6% and the S&P 500 gained 1.21% [1] - The company is expected to report an EPS of $0.58, reflecting a 16% increase from the same quarter last year, with a projected quarterly revenue of $4.03 billion, up 14.36% year-over-year [1] Full Year Estimates - For the full year, earnings are projected at $2.40 per share and revenue at $16.26 billion, indicating increases of +17.07% and +14.22% respectively from the previous year [2] Analyst Sentiment - Recent changes to analyst estimates for Boston Scientific indicate positive sentiment, suggesting optimism regarding the company's business and profitability [2] - The Zacks Rank system currently rates Boston Scientific at 2 (Buy), with a historical average annual return of +25% for 1 rated stocks since 1988 [3] Valuation Metrics - Boston Scientific has a Forward P/E ratio of 35.05, compared to the industry average of 24.52, indicating it is trading at a premium [3] - The company has a PEG ratio of 2.79, while the Medical - Products industry has an average PEG ratio of 2 [3] Industry Overview - The Medical - Products industry is part of the Medical sector and holds a Zacks Industry Rank of 50, placing it in the top 20% of over 250 industries [4] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

Boston Scientific’s (BSX) growth is backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Consistent MedSurg market share gain is also highly encouraging. Meanwhile, headwinds such as currency movements raise concern for Boston Scientific.In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 63.3% compared with the industry’s 26.5% growth and the S&P 500 compos ...

-Company to also host virtual webcast with a cardiology business update-MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will ...

MedTech manufacturers, who were literally hankering for the easing of monetary policy following a prolonged period of challenging business scenarios, probably heaved a sigh of relief after September’s aggressive rate cut. The highly-anticipated 50-bps rate cut by the Fed, bringing the federal funds rate to a 4.75% to 5% target range, is considered a turning point in overcoming the ongoing challenges of a period of decline and decadence within the MedTech space.With a high probability of another half a perce ...

Boston Scientific Corporation (BSX) recently received the Pharmaceuticals and Medical Device Agency’s (“PMDA”) approval in Japan for its FARAPULSE Pulsed Field Ablation (“PFA”) System. The FARAPULSE PFA System is used for treating paroxysmal atrial fibrillation (AF).Boston Scientific expects to launch the FARAPULSE PFA System in Japan in the upcoming weeks to treat approximately 1 million people affected by AF.BSX’s Likely Stock Trend Following the NewsSubsequent to the announcement, shares of BSX moved nor ...